This radiolabeled peptide—assessed in the following two different xenograft tumor models: MDA-MB-435 human breast carcinoma [28] and PC3-M human prostate carcinoma cells [29]—appeared to be a valuable radiopharmaceutical for the imaging of Gal-3 positive tumors by SPECT. Here, LGALS3 is linked to neoplasm.